Stocks · News reference

Guggenheim Downgrades AtaiBeckley to Neutral

Jul 17, 2026, 12:29 PMBenzinga Newsdesk

Guggenheim analyst Eddie Hickman downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Neutral.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 17, 2026, 12:29 PM
Checked: Jul 17, 2026, 12:29 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 18, 2026, 5:35 PMBenzinga Newsdesk
President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.
Read original at benzinga
ATAI PBM SILO XTLB
BenzingaAug 12, 2026, 4:18 PMAvi Kapoor
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Read original at benzinga
APGE ATAI CSQR LEGN ONON
BenzingaAug 12, 2026, 11:53 AMAvi Kapoor
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
Read original at benzinga
AMTM APP ATAI BLTE CAVA
BenzingaAug 12, 2026, 9:57 AMBenzinga Newsdesk
Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8
Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.
Read original at benzinga
ATAI